News | Artificial Intelligence | November 28, 2021

Breadth and depth of integrations across lung imaging acquisition, reading and reporting and care coordination enhance customer workflow and access

November 28, 2021 — Riverain Technologies, a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, announced the growth of its relationships across the lung imaging ecosystem at the 107th Annual Radiological Society of North America (RSNA) meeting, scheduled Nov. 28 – Dec. 2, 2021 (South Hall, booth #4129).

Riverain’s partnerships with OEMs, AI vendors, PACS providers, and reporting and patient management companies have grown in depth and breadth, providing customers with a more seamless enterprise-wide access to earlier, more efficient detection of lung abnormalities.

“Riverain was proud to introduce the first FDA approved chest algorithm almost 10 years ago and we are dedicated to continuously enhance our technology to improve clinical accuracy and efficiency,” said Steve Worrell, CEO. “At the same time, by expanding partnerships with key players across the ecosystem, we continue to deliver on an important promise to our users: your acquisition, your workflow, your peace-of-mind.”

Riverain will highlight its many strategic partnerships complementing the ClearRead suite of applications, providing enhanced end-to-end lung imaging and cancer screening capabilities:

  • Acquisition: expanded partnerships with multiple OEMs as well as other AI vendors to ensure the most complete and clinically relevant solutions possible. New partnerships include Aidoc, Imbio, and Volpara Health

  • Reading: enhanced collaboration with PACS vendors such as Nuance and Sectra to ensure a workflow so seamless that it’s almost invisible

  • IT integration: working with AI orchestrators to ensure easy access to functionality at every institution and in a purchasing/IT friendly manner

  • Care Coordination: developing relationships with and creating workflow enhancements to patient management and care coordination tools to ensure that patients who are found to have issues are followed and managed effectively.

ClearRead applications are approved for concurrent reading, saving radiologists time and steps in enhanced image review. The ClearRead suite significantly improves a clinician's ability to accurately and efficiently detect disease using patented vessel (CT) and bone (X-ray) suppression technology in thoracic images—for earlier, more efficient detection of lung abnormalities. Visit Riverain/RSNA to schedule an appointment.

For more information:

Related Content

News | Digital Radiography (DR)

January 25, 2022 — Carestream Health was awarded 45 new patents in 2021 for global advances in artificial intelligence ...

Time January 26, 2022
News | Lung Imaging

January 25, 2022 — A new study based on data from a national cancer registry in Taiwan found evidence that lung cancer ...

Time January 25, 2022
Sponsored Content | Videos | Magnetic Resonance Imaging (MRI)

With the recent launch of the Magnifico Open, Italian company Esaote has entered the open MRI whole body space. ITN had ...

Time January 24, 2022
News | Radiology Business

January 21, 2022 — IBM and Francisco Partners, a leading global investment firm that specializes in partnering with ...

Time January 21, 2022
News | Artificial Intelligence

January 20, 2022 — Leading health tech firm has gained 510(k) clearance from the Food and Drug Administration ...

Time January 20, 2022
Feature | Vendor Neutral Archive (VNA)

Vendor neutral archives (VNAs) have become a staple within the healthcare IT system. At the Radiological Society of ...

Time January 20, 2022
Feature | Radiology Business | By Jef Williams

The Great Resignation has impacted every industry, including ours. While this movement will be studied for years to come ...

Time January 20, 2022
Feature | Artificial Intelligence | By Dave Fornell, ITN Editor

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

Time January 19, 2022
Feature | Coronavirus (COVID-19) | By Avielle Siegel, Paul J. Chang, David M. Paushter, et al.

A 26-year-old man with history of diabetes and hypertension presented with 7 days of fever, chills, nausea, intractable ...

Time January 19, 2022
Sponsored Content | Case Study | Ultrasound Imaging

The most common cause of chronic liver disease? Nonalcoholic fatty liver disease (NAFLD). With 25% of the world’s ...

Time January 19, 2022
Subscribe Now